NHS Approves Drug to Prevent Menopausal Hot Flushes

Published: 11 March 2026 The English Chronicle Desk The English Chronicle Online – UK News

Women in England experiencing debilitating menopausal hot flushes will soon be able to access a new drug on the NHS, after health regulators approved its use in a landmark decision hailed as a breakthrough for women’s health.

The medicine, fezolinetant, works by targeting the brain’s temperature control centre rather than hormones, offering relief for women who cannot or do not wish to take hormone replacement therapy (HRT). Clinical trials show it can reduce the frequency and severity of hot flushes by more than half, providing a non‑hormonal alternative for thousands of women.

The National Institute for Health and Care Excellence (NICE) confirmed on Tuesday that fezolinetant will be made available to eligible patients across England. The decision follows years of campaigning by women’s health advocates, who argued that the NHS needed to expand treatment options for menopause symptoms beyond HRT.

Hot flushes affect around 80% of women during menopause, with one in four experiencing severe symptoms that disrupt sleep, work and daily life. For decades, HRT has been the primary treatment, but it is not suitable for all women—particularly those with a history of breast cancer or cardiovascular disease.

Fezolinetant, developed by Japanese pharmaceutical company Astellas, belongs to a new class of drugs known as neurokinin‑3 receptor antagonists. By acting directly on the hypothalamus, the brain’s temperature regulator, it reduces the sudden surges of heat and sweating that characterise hot flushes.

Professor Lucy Chappell, chief scientific adviser at the Department of Health, described the approval as “a significant step forward.” She said: “This is the first non‑hormonal medicine licensed specifically for hot flushes. It offers hope to women who have struggled for years without effective treatment.”

Trials involving more than 2,000 women showed that fezolinetant reduced hot flushes by 60% within 12 weeks. Participants also reported improved sleep and quality of life. Side‑effects were generally mild, including headaches and nausea, though liver function monitoring will be required.

Dr Paula Briggs, chair of the British Menopause Society, said: “This is a game‑changer. For women who cannot take HRT, there has been very little else to offer. Fezolinetant provides a safe and effective alternative.”

NICE’s guidance means the drug will be available on prescription within weeks. It will be offered to women experiencing moderate to severe hot flushes who cannot use HRT or who prefer a non‑hormonal option.

The NHS rollout is expected to benefit tens of thousands of women initially, with numbers likely to grow as awareness increases. Campaigners say the decision reflects a broader shift in attitudes toward menopause, which has historically been under‑researched and under‑funded.

The approval comes amid growing recognition of the impact of menopause on women’s health and careers. Surveys show that many women feel unsupported at work, with symptoms leading some to reduce hours or leave jobs altogether. The government has pledged to improve workplace policies and expand access to menopause care.

In recent years, demand for HRT has surged, leading to shortages and highlighting the need for alternative treatments. Fezolinetant’s arrival is expected to ease pressure on supply chains while offering choice to patients.

Women’s health campaigners welcomed the decision but urged continued investment in menopause services. Kate Muir, author and activist, said: “This is fantastic news, but it must be accompanied by better training for doctors and more specialist clinics. Too many women still struggle to access basic care.”

Pharmaceutical experts noted that the drug’s approval could pave the way for further innovation. Other neurokinin‑3 antagonists are in development, raising hopes of a new generation of non‑hormonal therapies.

The NHS’s decision to offer fezolinetant marks a milestone in women’s health. For the first time, women in England will have access to a non‑hormonal medicine specifically designed to prevent hot flushes.

While not a cure‑all, the drug represents progress toward greater choice, better care and recognition of the challenges women face during menopause. As Professor Chappell put it: “This is about giving women options, dignity and support at a crucial stage of life.”

Read More At>>